IL-17A, another important biologic target of psoriasis, plays a vital role in the pathogenesis of both psoriasis, and atherosclerotic plaques that accumulating evidence supports a beneficial influence of its agonists on related cardiometabolic comorbidities (Roubille et al., 2015; Lockshin et al., 2018). Here, IL17A is linked to psoriasis.